OSU-03012 (AR-12) 化学構造
分子量: 460.45

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare PDK-1 Inhibitors
    PDK-1製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSU-03012 (AR-12)は有効的に再編PDK-1を抑制、IC50が5µMになる。
ターゲット PDK-1
IC50 5 μM [1]
In vitro試験 OSU-03012 induces apoptotic death in PC-3 cells with IC50 of 5 µM and reduces the activity of immunoprecipitated p70S6K. OSU-03012 completely suppress cell growth in a diverse range of tumor cell lines at concentrations of 3–5 μm, as compared with the concentration of at least 50 μm required for celecoxib. [1] OSU-03012 promotes cell killing to a greater extent in glioma cells than in nontransformed astrocytes. OSU-03012 causes a dose-dependent induction of cell death that is not altered by p53 mutation, expression of ERBB1 VIII, or loss of phosphatase and tensin function due to a homolog deletion on chromosome 10. OSU-03012 and ionizing radiation cause an additive, caspase-independent elevation in cell killing. OSU-03012 lethality as a single agent or when combined with signaling modulators is not modified in cells lacking expression of BIM or of BAX/BAK. OSU-03012 promotes the release of cathepsin B from the lysosomal compartment and that of AIF from mitochondria. The lethality of OSU-03012 is attenuated in protein kinase R-like endoplasmic reticulum kinase-/- cells, which correlated with the reduced cleavage of BID and suppression of cathepsin B and AIF release into the cytosol. [2] OSU-03012 inhibits thyroid cancer cell (NPA, WRO, and ARO cells) proliferation, migration and induces apoptosis, which results in an increase of cells in the S phase without an increase of cells in G2. OSU-03012 is an ATP-competitive inhibitor of PAK activity and suppresses the phosphorylation of AKT in thyroid cancer cells. [3] OSU-03012 inhibits cell growth of hepatocellular carcinoma cell lines including Huh7, Hep3B and HepG2 cells with IC50 values below 1 μM. OSU-03012 does not suppress PDK1 or AKT activity or induce cellular apoptosis but induces autophagy in Huh7 cells. Moreover, accumulation of reactive oxygen species (ROS) is detected after OSU-03012 treatment. [4] A recent study shows that OSU-03012 could enhance the susceptibility of (Bcr)-Abl mutant cell lines to imatinib-induced apoptosis. [5]
In vivo試験 OSU-03012 suppresses tumor growth by 57.59% and increases cleaved LC3 in Huh7 tumor xenografts at 200 mg/kg. [4] OSU-03012 remarkably decreases expression of EGFR protein in the tumors by 48% compared with vehicle controls and also prevents YB-1 from binding to the EGFR promoter in MDA-MB-435/LCC6 xenografts. [6] OSU-03012 is well tolerated and inhibits the growth of HMS-97 schwannoma xenografts by 55% after oral administration. [7]
臨床試験
特集 A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

PDK-1 Kinase Assay This in vitro assay is performed using a PDK-1 kinase assay kit. This cell-free assay is based on the ability of recombinant PDK-1, in the presence of DMSO vehicle or OSU-03012, to activate its downstream serum- and glucocorticoid-regulated kinase which, in turn, phosphorylates the Akt/serum- and glucocorticoid-regulated kinase-specific peptide substrate RPRAATF with [γ-32P]ATP. The 32P-phosphorylated peptide substrate is then separated from the residual [γ-32P]-ATP by using P81 phosphocellulose paper and quantitated in a scintillation counter after three washes with 0.75% phosphoric acid.

細胞アッセイ: [1]

細胞株 PC-3 cells
濃度 0-10 μM
反応時間 ~72 hours
実験の流れ The effect of OSU-03012 on PC-3 cell viability is assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay in six replicates. Cells are grown in 10% FBS- supplemented RPMI 1640 in 96-well, flat-bottomed plates for 24 hours. They are exposed to various concentrations of OSU-03012 (0-10 μM) dissolved in DMSO (final concentration ≤0.1%) in 1% serum-containing RPMI 1640 for different time intervals (~72 hours). Controls receive DMSO vehicle at a concentration equal to that in OSU-03012-treated cells. The medium is removed and replaced by 200 μL of 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in 10% FBS-containing RPMI 1640. The cells are incubated in the CO2 incubator at 37 °C for 2 hours. Supernatants are removed from the wells, and the reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye is solubilized in 200 μL DMSO per well. Absorbance at 570 nm is determined by using a plate reader.

動物実験: [4]

動物モデル Huh7 tumor xenografts in male BALB/c nude mice
製剤 Dissolved in 0.5% methylcellulose, 0.1% Tween 80
投薬量 100-200 mg/kg
投与方法 Daily by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSU-03012 (AR-12) SDF
分子量 460.45
化学式

C26H19F3N4O

CAS No. 742112-33-0
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 11 mg/mL (23.88 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide

カスタマーフィードバック (3)


Click to enlarge
Rating
Source J Biol Chem, 2014, 289(38), 26155-66. OSU-03012 (AR-12) purchased from Selleck
Method Western blot
Cell Lines HEK293-AT1A cells
Concentrations 10 uM
Incubation Time 6 h
Results It shows the effects of PD98059 and OSU03012 on basal Akt phosphorylation in HEK293-AT1A cells. As expected, no significant change in total cellular phospho-Akt was measurable in response to AngII or SII exposure. Importantly, while the PDK1 inhibitor, OSU03012, dramatically reduced global Akt phosphorylation, the MEK1/2 inhibitor PD98059 had no effect, demonstrating that it did not nonspecifically affect Akt activity at the concentration employed.

Click to enlarge
Rating
Source PLoS One, 2013, 8, e75100. OSU-03012 (AR-12) purchased from Selleck
Method Western blot
Cell Lines Orbital fibroblasts
Concentrations 5 uM
Incubation Time 6 h
Results The siRNA targeting PDK1 attenuates TSH-dependent PKCm Ser 916 phosphorylation in fibroblasts (Fig. C) while the PDK1 inhibitor, OSU-03012 (5 mM) [54] blocks TSH-dependent phosphorylation of PKCm Ser 916 and PKCbII Ser 660 levels in the respective cell-types (Fig. C). The inhibitor also reduces levels of TSH-dependent pAKT Threonine 308 in fibroblasts but fails to do so in fibrocytes (Fig. D, 14.461.2% and 2.560.6%, respectively).

Click to enlarge
Rating
Source Anticancer Drugs, 2013, 24(7), 690-8. OSU-03012 (AR-12) purchased from Selleck
Method TUNEL assay
Cell Lines Eca-109 cells
Concentrations 2 uM
Incubation Time 24 h
Results It investigated whether it could induce apoptosis in Eca-109 cells by the TUNEL assay. As shown, apoptotic cells were detected after 24 h of treatment with OSU-03012. Control Eca-109 cells showed 11.3±5% TUNEL-positive cells, whereas Eca-109 cells treated with 2 mmol/l OSU-03012 showed 56.9±2% TUNEL-positive cells.

文献中の引用 (12)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PDK-1 阻害剤

  • LY2090314

    LY2090314 は GSK-3α と GSK-3βのために、強力なGSK-3阻害剤で、IC50 がそれぞれ1.5 nM と 0.9 nMです。

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • BX-795

    BX-795 は強い、比較的、具体的なtbk1とIKKεキナーゼ阻害剤、IC50 がそれぞれ 6 nM と 41 nM。

  • BX-912

    BX-912は選択的な強力なPDK1阻害剤で、 IC50 が 12 nMになる。

  • GSK2334470

    GSK2334470 is a novel and highly specific inhibitor of PDK1 with IC50 of ~10 nM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • MK-2206 2HCl

    MK-2206 2HClは高度選択的に Akt1, Akt2 and Akt3を抑制して、 IC50がそれぞれ 8 nM, 12 nM と 65 nMになる。

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

最近チェックしたアイテム

Tags: OSU-03012 (AR-12)を買う | OSU-03012 (AR-12)供給者 | OSU-03012 (AR-12)を購入する | OSU-03012 (AR-12)費用 | OSU-03012 (AR-12)生産者 | オーダーOSU-03012 (AR-12) | OSU-03012 (AR-12)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ